Ann: AdAlta to present at IRD Invest virtual conference, page-9

Thanks for the link. Confirmation that prospective pharmaceutical partners are eagerly awaiting data from the Phase 1 trial. The usual lot for biotech's is to develop products and do the rounds of international conferences to try and generate interest in the therapeutic program and sell the data to Pharma.

It appears they're lined up at the door. Mind you, AdAlta has done its fair share of conferences which has come off the back of a decade of intense scientific endeavour. My personal thanks to Sam for a conference that I attended on the Gold Coast in mid 2019.

We also find out that a window for partnering AD-214 will appear towards the end of Phase 1, towards the back end of 2021. Lets take stock. That's Phase 1 or even towards the end of Phase 1. The timetable suggests that there is remarkable interest in the AD-214 program. Put on our COVID-19 glasses and we get greater clarity in understanding the interest in a small Australian biotech that long ago chose IPF as the disease indication.